Retatrutide UK — What It Is, How It Works & UK Availability (2026)

Retatrutide is a synthetic peptide developed by Eli Lilly under the compound code LY-3437943. It belongs to the incretin family — the same broad class as Semaglutide and Tirzepatide — but differs in how many receptors it engages.

Where Semaglutide targets a single receptor and Tirzepatide targets two, Retatrutide targets three. That is the entire reason it became the flagship compound of the current metabolic research generation, and the reason search interest in it in the UK has grown faster than for any other peptide in the class.

A receptor agonist is a molecule that binds to a receptor and switches it on. Retatrutide switches on three:

• GLP-1 receptor — the pathway associated in published research with satiety signalling, slowed gastric emptying and glucose-dependent insulin release. This is the only pathway Semaglutide engages.
• GIP receptor — the second incretin pathway. Adding it is what distinguished Tirzepatide from the single-agonist generation before it.
• Glucagon receptor — the pathway unique to Retatrutide in this class. Glucagon-receptor activation is associated in the literature with increased energy expenditure and hepatic lipid metabolism, rather than appetite suppression alone.

The research interest is in the combination: the two incretin pathways influence intake while the glucagon pathway influences expenditure, so the compound acts on both sides of the energy balance rather than one.

Eli Lilly's Phase 2 programme was published in the New England Journal of Medicine in 2023. Across escalating dose cohorts it reported the largest weight-related endpoints recorded for any GLP-family compound at that stage of development, with results scaling by dose over the trial period.

The trials also recorded dose-dependent gastrointestinal effects and increases in heart rate at higher doses, both of which are discussed openly in the published papers. Phase 3 trials (TRIUMPH) are still ongoing, and no regulator anywhere has licensed Retatrutide.

That unfinished regulatory status is the single most important fact about Retatrutide in 2026: the data is striking, the compound is not approved, and it is not available as a medicine in the UK.

• Semaglutide — single agonist (GLP-1 only). The original of the class.
• Tirzepatide — dual agonist (GLP-1 + GIP). The current benchmark.
• Retatrutide — triple agonist (GLP-1 + GIP + glucagon). The newest and least far along in trials.

See the full side-by-side breakdowns in our Retatrutide vs Tirzepatide guide, Retatrutide vs Semaglutide guide and our Retatrutide vs Mounjaro comparison.

Published Retatrutide trial literature most commonly reports mild-to-moderate gastrointestinal effects — nausea, reduced appetite and occasional GI upset. These were dose-dependent and typically transient, and were most pronounced during dose escalation. Higher-dose cohorts also showed modest heart-rate increases.

As with all GLP-family compounds, slow and cautious titration is standard practice in research protocols. This section summarises published research only, is not medical advice, and Retatrutide is not for human use.

Full breakdown: Retatrutide side effects UK guide.

Retatrutide is not a licensed medicine in the UK. It cannot be prescribed by the NHS, by a private GP or by an online pharmacy, and any UK service claiming to prescribe it is not supplying a licensed product. Licensing would require completion of the Phase 3 programme and MHRA approval, neither of which has happened.

It is, however, legal to purchase and possess in the UK for laboratory research purposes. That is the only basis on which it is supplied here — as a research peptide, for in vitro use, not for human consumption.

Retatrutide is supplied lyophilised (freeze-dried) and must be reconstituted with bacteriostatic water — typically 2–4ml depending on the protocol. Add the water slowly down the side of the vial and do not shake, as agitation can damage the peptide chain. Once dissolved, refrigerate at 2–8°C and use within 28 days.

Use our free peptide reconstitution calculator for exact volumes and insulin-syringe units, the full Retatrutide dosage chart, or the general reconstitution guide.

Because Retatrutide is unlicensed, quality varies enormously between suppliers and there is no regulator checking what is in the vial. Before buying from anyone, check:

• A batch-matched Certificate of Analysis — the batch number on the vial should match a published COA, not a generic PDF.
• Independent HPLC and mass-spec testing — HPLC gives purity, mass-spec confirms it is actually the right molecule.
• Where the stock physically sits — UK-held stock avoids customs seizure and long transit at ambient temperature.
• Whether the vial is sealed and tamper-evident on arrival, and properly lyophilised rather than partially collapsed.
• Whether payment is normal card checkout — crypto-only checkouts are usually a sign the supplier cannot hold a UK merchant account.

Every batch we stock is independently HPLC and mass-spec tested at 99%+ purity with the Certificate of Analysis published here.

Peptides UK 4U stocks Retatrutide in 20mg, 30mg and 40mg vials, held in the UK and dispatched the same working day. You deal with a UK business, not an overseas reshipper.

• Retatrutide 20mg — entry vial, ideal for shorter protocols or first evaluation.
• Retatrutide 30mg — our most popular size for ongoing research.
• Retatrutide 40mg — best £/mg value for extended projects.
• UK stock — no customs, no multi-week waits.
• Same-day dispatch before 2pm (Mon–Fri), Royal Mail Tracked 24 with photo confirmation.
• Discreet plain packaging and normal UK card checkout — no crypto required.

Prefer not to reconstitute? We also prepare pre-filled Retatrutide pens in all three strengths, with a clicks-per-mg usage guide.